Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Myelodysplastic syndrome

S J Forman1

  • 1City of Hope National Medical Center, Duarte, CA, USA.

Current Opinion in Hematology
|July 1, 1996
PubMed
Summary
This summary is machine-generated.

Myelodysplasia is increasingly diagnosed in younger patients and as a complication of chemotherapy. Research is advancing our understanding of therapy-related myelodysplasia and its genetic links.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors.

Leukemia·2016
Same author

Mycophenolate mofetil-based salvage as acute GVHD prophylaxis after early discontinuation of tacrolimus and/or sirolimus.

Bone marrow transplantation·2014
Same author

Sclerodermatous chronic GVHD in patients receiving tyrosine kinase inhibitors after allogeneic hematopoietic cell transplantation.

Bone marrow transplantation·2014
Same author

Real-time assessment of relapse risk based on the WT1 marker in acute leukemia and myelodysplastic syndrome patients after hematopoietic cell transplantation.

Bone marrow transplantation·2014
Same author

Efficient selection of genetically modified human T cells using methotrexate-resistant human dihydrofolate reductase.

Gene therapy·2013
Same journal

Dynamic myeloid suppressor states in cancer and inflammation and their therapeutic potential.

Current opinion in hematology·2026
Same journal

Factor XIa inhibition for the prevention of thrombosis: mechanism, clinical trial signals, and indication-specific positioning.

Current opinion in hematology·2026
Same journal

Nutrition as a regulator of hematopoietic stem cell biology and transplantation.

Current opinion in hematology·2026
Same journal

From biomimicry to clinical actionability: rethinking high-shear thrombosis as a mechanobiological system.

Current opinion in hematology·2026
Same journal

Bidirectional relationship between metabolic and thrombotic disease mechanisms.

Current opinion in hematology·2026
Same journal

The dual role of the brain-derived neurotrophic factor as a regulator of hemostasis and thrombotic risk.

Current opinion in hematology·2026
See all related articles

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Background:

  • Myelodysplasia is increasingly recognized in both elderly and younger populations.
  • It is also emerging as a complication following chemotherapy treatments.
  • Recent research has focused on differentiating therapy-related myelodysplasia subtypes and their genetic underpinnings.

Purpose of the Study:

  • To review recent advances in understanding myelodysplasia, particularly therapy-related forms.
  • To discuss the genetic associations within different myelodysplasia subtypes.
  • To explore potential future therapeutic strategies for myelodysplasia.

Main Methods:

  • Review of current scientific literature on myelodysplasia.
  • Analysis of recent findings on therapy-related myelodysplasia.

Related Experiment Videos

  • Examination of genetic associations and stem cell biology in myelodysplasia.

    • Main Results:

    • Distinction between different forms of therapy-related myelodysplasia.
    • Identification of specific genetic associations with myelodysplasia subtypes.
    • Evidence of a normal stem cell compartment in myelodysplastic bone marrow.

    Conclusions:

    • Allogeneic bone marrow transplantation remains the primary curative option for myelodysplasia.
    • Understanding the normal stem cell compartment opens avenues for future therapies.
    • Autologous stem cell transplantation may become a viable option post-remission chemotherapy.